PURPOSE: To estimate the mean rates of ocular function loss in patients with autosomal recessive retinitis pigmentosa due to USH2A mutations. METHODS: In 125 patients with USH2A mutations, longitudinal regression was used to estimate mean rates of change in Snellen visual acuity, Goldmann visual field area (V4e white test light), and 30-Hz (cone) full-field electroretinogram amplitude. These rates were compared with those of previously studied cohorts with dominant retinitis pigmentosa due to RHO mutations and with X-linked retinitis pigmentosa due to RPGR mutations. Rates of change in patients with the Cys759Phe mutation, the USH2A mutation associated with nonsyndromic disease, were compared with rates of change in patients with the Glu767fs mutation, the most common USH2A mutation associated with Usher syndrome type II (i.e., retinitis pigmentosa and hearing loss). RESULTS: Mean annual exponential rates of decline for the USH2A patients were 2.6% for visual acuity, 7.0% for visual field area, and 13.2% for electroretinogram amplitude. The rate of acuity loss fell between the corresponding rates for the RHO and RPGR patients, whereas the rates for field and ERG amplitude loss were faster than those for the RHO and RPGR patients. No significant differences were found for patients with the Cys759Phe mutation versus patients with the Glu767fs mutation. CONCLUSIONS: On average, USH2A patients lose visual acuity faster than RHO patients and slower than RPGR patients. USH2A patients lose visual field and cone electroretinogram amplitude faster than patients with RHO or RPGR mutations. Patients with a nonsyndromic USH2A mutation have the same retinal disease course as patients with syndromic USH2A disease.
PURPOSE: To estimate the mean rates of ocular function loss in patients with autosomal recessive retinitis pigmentosa due to USH2A mutations. METHODS: In 125 patients with USH2A mutations, longitudinal regression was used to estimate mean rates of change in Snellen visual acuity, Goldmann visual field area (V4e white test light), and 30-Hz (cone) full-field electroretinogram amplitude. These rates were compared with those of previously studied cohorts with dominant retinitis pigmentosa due to RHO mutations and with X-linked retinitis pigmentosa due to RPGR mutations. Rates of change in patients with the Cys759Phe mutation, the USH2A mutation associated with nonsyndromic disease, were compared with rates of change in patients with the Glu767fs mutation, the most common USH2A mutation associated with Usher syndrome type II (i.e., retinitis pigmentosa and hearing loss). RESULTS: Mean annual exponential rates of decline for the USH2Apatients were 2.6% for visual acuity, 7.0% for visual field area, and 13.2% for electroretinogram amplitude. The rate of acuity loss fell between the corresponding rates for the RHO and RPGRpatients, whereas the rates for field and ERG amplitude loss were faster than those for the RHO and RPGRpatients. No significant differences were found for patients with the Cys759Phe mutation versus patients with the Glu767fs mutation. CONCLUSIONS: On average, USH2Apatients lose visual acuity faster than RHO patients and slower than RPGRpatients. USH2Apatients lose visual field and cone electroretinogram amplitude faster than patients with RHO or RPGR mutations. Patients with a nonsyndromic USH2A mutation have the same retinal disease course as patients with syndromic USH2A disease.
Authors: S Bernal; C Ayuso; G Antiñolo; A Gimenez; S Borrego; M J Trujillo; I Marcos; M Calaf; E Del Rio; M Baiget Journal: J Med Genet Date: 2003-01 Impact factor: 6.318
Authors: B Dreyer; L Tranebjaerg; V Brox; T Rosenberg; C Möller; M Beneyto; M D Weston; W J Kimberling; C W Cremers; X Z Liu; O Nilssen Journal: Am J Hum Genet Date: 2001-06-08 Impact factor: 11.025
Authors: M D Weston; J D Eudy; S Fujita; S Yao; S Usami; C Cremers; J Greenberg; R Ramesar; A Martini; C Moller; R J Smith; J Sumegi; W J Kimberling; J Greenburg Journal: Am J Hum Genet Date: 2000-03-22 Impact factor: 11.025
Authors: J D Eudy; M D Weston; S Yao; D M Hoover; H L Rehm; M Ma-Edmonds; D Yan; I Ahmad; J J Cheng; C Ayuso; C Cremers; S Davenport; C Moller; C B Talmadge; K W Beisel; M Tamayo; C C Morton; A Swaroop; W J Kimberling; J Sumegi Journal: Science Date: 1998-06-12 Impact factor: 47.728
Authors: Babak Jian Seyedahmadi; Carlo Rivolta; Julia A Keene; Eliot L Berson; Thaddeus P Dryja Journal: Exp Eye Res Date: 2004-08 Impact factor: 3.467
Authors: Dror Sharon; Michael A Sandberg; Vivian W Rabe; Melissa Stillberger; Thaddeus P Dryja; Eliot L Berson Journal: Am J Hum Genet Date: 2003-10-16 Impact factor: 11.025
Authors: Ronald J E Pennings; Patrick L M Huygen; Dana J Orten; Mariette Wagenaar; Annelies van Aarem; Hannie Kremer; William J Kimberling; Cor W R J Cremers; August F Deutman Journal: Acta Ophthalmol Scand Date: 2004-04
Authors: Terri L McGee; Babak Jian Seyedahmadi; Meredith O Sweeney; Thaddeus P Dryja; Eliot L Berson Journal: J Med Genet Date: 2010-05-27 Impact factor: 6.318
Authors: Wadih M Zein; Benedetto Falsini; Ekaterina T Tsilou; Amy E Turriff; Julie M Schultz; Thomas B Friedman; Carmen C Brewer; Christopher K Zalewski; Kelly A King; Julie A Muskett; Atteeq U Rehman; Robert J Morell; Andrew J Griffith; Paul A Sieving Journal: Invest Ophthalmol Vis Sci Date: 2014-11-25 Impact factor: 4.799
Authors: Eliot L Berson; Carol Weigel-DiFranco; Bernard Rosner; Alexander R Gaudio; Michael A Sandberg Journal: JAMA Ophthalmol Date: 2018-05-01 Impact factor: 7.389
Authors: Edwin M Stone; Xunda Luo; Elise Héon; Byron L Lam; Richard G Weleber; Jennifer A Halder; Louisa M Affatigato; Jacqueline B Goldberg; Alexander Sumaroka; Sharon B Schwartz; Artur V Cideciyan; Samuel G Jacobson Journal: Invest Ophthalmol Vis Sci Date: 2011-12-28 Impact factor: 4.799
Authors: Tharikarn Sujirakul; Michael K Lin; Jimmy Duong; Ying Wei; Sara Lopez-Pintado; Stephen H Tsang Journal: Am J Ophthalmol Date: 2015-07-09 Impact factor: 5.258
Authors: Kevin T Booth; Hela Azaiez; Kimia Kahrizi; Allen C Simpson; William T A Tollefson; Christina M Sloan; Nicole C Meyer; Mojgan Babanejad; Fariba Ardalani; Sanaz Arzhangi; Michael J Schnieders; Hossein Najmabadi; Richard J H Smith Journal: Am J Med Genet A Date: 2015-09-29 Impact factor: 2.802
Authors: Margo Dona; Ralph Slijkerman; Kimberly Lerner; Sanne Broekman; Jeremy Wegner; Taylor Howat; Theo Peters; Lisette Hetterschijt; Nanda Boon; Erik de Vrieze; Nasrin Sorusch; Uwe Wolfrum; Hannie Kremer; Stephan Neuhauss; Jingjing Zang; Maarten Kamermans; Monte Westerfield; Jennifer Phillips; Erwin van Wijk Journal: Exp Eye Res Date: 2018-05-16 Impact factor: 3.467